Cenicriviroc treatment for adults with non-alcoholic steatohepatitis: Year 2 analysis of the Phase 2b CENTAUR study
EASL LiverTree™. Ratziu V. Apr 12, 2018; 210644 Topic: Prognosis
Prof. Vlad Ratziu
Prof. Vlad Ratziu
Contributions
Learning Objectives
Abstract
After viewing this presentation the participant will be able to:

- Review efficacy, safety, and reduction of inflammation data for year 2 of the CENTAUR study testing antifibrotic response with CVC treatment
- Discuss the similarities and differences of the antifibrotic response with CVC following 1 and 2 years of treatment
GS-002

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies